Pub Date : 2026-02-01DOI: 10.1016/j.jaccao.2025.12.003
Darryl Leong, Selena Gong, Naveed Sattar, Vivek Narayan, Natalie M Reizine, Hertzel Gerstein, Jordan Vellky
Incretin mimetics (glucagon-like peptide-1 receptor agonists and dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonists) are paradigm changing for managing obesity, diabetes, and cardiovascular risk. These phenotypes are also associated with elevated risk for numerous cancers. Limited research suggests that incretin mimetics may be associated with lower risk for developing several cancers. However, more translational and randomized clinical data are needed for confirmation. Patients with cancer were excluded from trials of incretin mimetics. Therefore, their effects on adipose tissue, muscle, cardiovascular risk factors, and outcomes in this population are unknown. Notwithstanding contraindications with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, translational data also promote the hypothesis that incretin mimetics could slow the growth of other cancers. Further clinical data are needed to determine which patients undergoing cancer treatment might experience benefit or harm from the anthropometric and calorie reduction effects of incretin mimetics or display cardiometabolic benefit despite the competing risk for cancer death.
{"title":"Incretin Mimetics in Cancer and Cardiovascular Disease: JACC: CardioOncology State-of-the-Art Review.","authors":"Darryl Leong, Selena Gong, Naveed Sattar, Vivek Narayan, Natalie M Reizine, Hertzel Gerstein, Jordan Vellky","doi":"10.1016/j.jaccao.2025.12.003","DOIUrl":"https://doi.org/10.1016/j.jaccao.2025.12.003","url":null,"abstract":"<p><p>Incretin mimetics (glucagon-like peptide-1 receptor agonists and dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonists) are paradigm changing for managing obesity, diabetes, and cardiovascular risk. These phenotypes are also associated with elevated risk for numerous cancers. Limited research suggests that incretin mimetics may be associated with lower risk for developing several cancers. However, more translational and randomized clinical data are needed for confirmation. Patients with cancer were excluded from trials of incretin mimetics. Therefore, their effects on adipose tissue, muscle, cardiovascular risk factors, and outcomes in this population are unknown. Notwithstanding contraindications with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, translational data also promote the hypothesis that incretin mimetics could slow the growth of other cancers. Further clinical data are needed to determine which patients undergoing cancer treatment might experience benefit or harm from the anthropometric and calorie reduction effects of incretin mimetics or display cardiometabolic benefit despite the competing risk for cancer death.</p>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 1","pages":"1-16"},"PeriodicalIF":12.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146221189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.jaccao.2025.11.002
Aron Onerup, Qi Liu, Shizue Izumi, José Miguel Martínez-Martínez, Stephanie B Dixon, Eric J Chow, Melissa M Hudson, Claire Snyder, Paul C Nathan, Gregory T Armstrong, Kirsten K Ness, Yutaka Yasui
{"title":"Potential of Exercise for Prevention of Cardiovascular Disease in Survivors of Childhood Hodgkin Lymphoma.","authors":"Aron Onerup, Qi Liu, Shizue Izumi, José Miguel Martínez-Martínez, Stephanie B Dixon, Eric J Chow, Melissa M Hudson, Claire Snyder, Paul C Nathan, Gregory T Armstrong, Kirsten K Ness, Yutaka Yasui","doi":"10.1016/j.jaccao.2025.11.002","DOIUrl":"https://doi.org/10.1016/j.jaccao.2025.11.002","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 1","pages":"87-89"},"PeriodicalIF":12.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146221573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.jaccao.2025.12.001
Javier E Sierra-Pagan, Michael G Levin
{"title":"Cardiovascular Risk Prediction in Breast Cancer Survivors: Are Polygenic Scores Ready for Prime Time?","authors":"Javier E Sierra-Pagan, Michael G Levin","doi":"10.1016/j.jaccao.2025.12.001","DOIUrl":"https://doi.org/10.1016/j.jaccao.2025.12.001","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 1","pages":"77-79"},"PeriodicalIF":12.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146221115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.jaccao.2025.12.004
Paolo Milani, Giuseppe Damiano Sanna, Mario Nuvolone, Giampaolo Merlini, Giovanni Palladini
{"title":"Reply: Refining Free Light Chain Ratio in Systemic Amyloidosis.","authors":"Paolo Milani, Giuseppe Damiano Sanna, Mario Nuvolone, Giampaolo Merlini, Giovanni Palladini","doi":"10.1016/j.jaccao.2025.12.004","DOIUrl":"https://doi.org/10.1016/j.jaccao.2025.12.004","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 1","pages":"99"},"PeriodicalIF":12.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146221537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.jaccao.2025.12.008
Olayiwola Bolaji, Samantha Brown, Brian C Shaffer, Glenn Heller, Marie-Claude Beaulieu, James E Ip, Carol L Chen, Sergio Giralt, Ioanna Kosmidou, Heather J Landau, Usmani Saad, Michael Scordo, Gunjan Shah, Roni Shouval, Anthony F Yu, Jennifer E Liu
Background: Atrial fibrillation (AF) is a common and clinically significant complication in cancer patients, but data on its incidence and impact among multiple myeloma (MM) patients undergoing autologous stem cell transplantation (ASCT) remain limited.
Objectives: The aim of this study was to characterize the incidence, predictors, and prognostic implications of AF following ASCT in MM patients.
Methods: A total of 801 MM patients who underwent ASCT between 2016 and 2022 were retrospectively analyzed. Pretransplantation evaluation included electrocardiography and echocardiography within 180 days of conditioning. Patients with AF at baseline were excluded. Post-transplantation AF was defined as electrocardiography-confirmed AF occurring after stem cell infusion.
Results: Over a median follow-up period of 36.2 months, 70 patients (8.7%) developed post-transplantation AF. The cumulative incidence was 5.5% at 90 days and 9.0% at 3 years, with a median onset of 13 days. Independent predictors included age >65 years (HR: 1.88; 95% CI: 1.16-3.07), prior paroxysmal AF (HR: 6.19; 95% CI: 3.63-10.5), and obesity (HR: 2.00; 95% CI: 1.10-3.63). Left atrial volume index >34 mL/m2 (HR: 1.67; 95% CI: 0.99-2.80) and corrected QT interval >480 ms (HR: 1.69; 95% CI: 0.91-3.12) were associated with AF but not statistically significant after adjustment. Among patients without prior AF, corrected QT interval >480 ms remained a significant predictor. In multivariable analysis, post-transplantation AF conferred a 5-fold higher risk for all-cause mortality and a 4.5-fold higher risk for nonrelapse mortality.
Conclusions: AF is a frequent and high-risk complication among MM patients undergoing ASCT. Routinely available clinical factors enable risk stratification, underscoring the importance of cardiovascular evaluation and vigilant post-transplantation monitoring in this vulnerable population.
{"title":"Atrial Fibrillation Following Autologous Stem Cell Transplantation in Multiple Myeloma: Incidence, Predictors, and Prognostic Impact.","authors":"Olayiwola Bolaji, Samantha Brown, Brian C Shaffer, Glenn Heller, Marie-Claude Beaulieu, James E Ip, Carol L Chen, Sergio Giralt, Ioanna Kosmidou, Heather J Landau, Usmani Saad, Michael Scordo, Gunjan Shah, Roni Shouval, Anthony F Yu, Jennifer E Liu","doi":"10.1016/j.jaccao.2025.12.008","DOIUrl":"https://doi.org/10.1016/j.jaccao.2025.12.008","url":null,"abstract":"<p><strong>Background: </strong>Atrial fibrillation (AF) is a common and clinically significant complication in cancer patients, but data on its incidence and impact among multiple myeloma (MM) patients undergoing autologous stem cell transplantation (ASCT) remain limited.</p><p><strong>Objectives: </strong>The aim of this study was to characterize the incidence, predictors, and prognostic implications of AF following ASCT in MM patients.</p><p><strong>Methods: </strong>A total of 801 MM patients who underwent ASCT between 2016 and 2022 were retrospectively analyzed. Pretransplantation evaluation included electrocardiography and echocardiography within 180 days of conditioning. Patients with AF at baseline were excluded. Post-transplantation AF was defined as electrocardiography-confirmed AF occurring after stem cell infusion.</p><p><strong>Results: </strong>Over a median follow-up period of 36.2 months, 70 patients (8.7%) developed post-transplantation AF. The cumulative incidence was 5.5% at 90 days and 9.0% at 3 years, with a median onset of 13 days. Independent predictors included age >65 years (HR: 1.88; 95% CI: 1.16-3.07), prior paroxysmal AF (HR: 6.19; 95% CI: 3.63-10.5), and obesity (HR: 2.00; 95% CI: 1.10-3.63). Left atrial volume index >34 mL/m<sup>2</sup> (HR: 1.67; 95% CI: 0.99-2.80) and corrected QT interval >480 ms (HR: 1.69; 95% CI: 0.91-3.12) were associated with AF but not statistically significant after adjustment. Among patients without prior AF, corrected QT interval >480 ms remained a significant predictor. In multivariable analysis, post-transplantation AF conferred a 5-fold higher risk for all-cause mortality and a 4.5-fold higher risk for nonrelapse mortality.</p><p><strong>Conclusions: </strong>AF is a frequent and high-risk complication among MM patients undergoing ASCT. Routinely available clinical factors enable risk stratification, underscoring the importance of cardiovascular evaluation and vigilant post-transplantation monitoring in this vulnerable population.</p>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 1","pages":"17-27"},"PeriodicalIF":12.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146221114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.jaccao.2025.12.005
Artur Schneider, Elizabeth A Mauricio, Melissa A Lyle
{"title":"Calling All Carriers: Closing the Gap in V142I Recognition.","authors":"Artur Schneider, Elizabeth A Mauricio, Melissa A Lyle","doi":"10.1016/j.jaccao.2025.12.005","DOIUrl":"https://doi.org/10.1016/j.jaccao.2025.12.005","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 1","pages":"45-47"},"PeriodicalIF":12.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146221152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号